蒙药乳腺-Ⅰ号对实验性大鼠乳腺增生的治疗作用及蛋白质组学研究
|
摘要
乳腺增生症是最常见的乳腺疾病,多见于30～50岁的中年妇女,占全部乳腺疾病的75%,在连续渐进的演变过程中可能发生癌变。近10年来,随着生活环境的变化,乳腺增生症发生率逐渐上升并趋向年轻化,以至于乳腺癌的发病率亦日趋增高,为此世界卫生组织在21世纪初提出了“提前干预乳腺增生症”的战略思想,已引起了医学界的广泛关注。乳腺增生症作为乳腺癌的风险因子之一,研究其发病机制,开发其治疗药物具有深远的现实意义。现代医学对于乳腺增生症的治疗尚无十分有效的方案,目前仍以内服激素和手术治疗为主,而民族医学对乳腺增生症的治疗具有丰富的经验,尤其是蒙药对乳腺增生症的治疗有独到之处。蒙药乳腺-Ⅰ号是内蒙古自治区的传统秘方,用其治疗符合蒙医“妇血症”又符合西医乳腺增生症标准的400例患者,总有效率为98%。但由于缺乏现代医学理论的支持,蒙药乳腺-Ⅰ号的开发力度及普及范围十分有限,仅作为院内制剂应用于临床。如果将现代医学的技术手段与蒙药乳腺-Ⅰ号研发相结合将会大大推动蒙药乳腺-Ⅰ号的开发与应用。如今在以功能基因组学和蛋白质组学为核心的后基因组时代,以高灵敏度和高通量检测为特点的药物蛋白质组学有望成为分析蒙药治疗机制的新方法。蛋白质组学研究技术的发展,为解析疾病的发病机制、寻找和发现药物治疗靶点创造了有利条件。运用蛋白质组学高通量地对比分析药物作用前后蛋白质表达谱或表达丰度的改变可筛选出与药物作用相关的蛋白靶点。近年来,蛋白质组学相关的实验技术不断涌现,如荧光差异双向凝胶电泳(2D-DIGE)技术,其与传统的双向电泳(2-DE)相比,提高了重复性,简化了比较模式,大大加宽了蛋白点检测的动态范围,已被广泛应用。
目前关于乳腺癌的蛋白质组学研究报道较多,而乳腺增生症蛋白质组学的相关报道并不多见,通过实验动物建立乳腺增生动物模型,进而对蒙药乳腺-Ⅰ号治疗作用的蛋白质组学研究迄今未见报道。本研究通过采用雌激素联合孕激素肌内注射的方法复制大鼠乳腺增生模型,利用形态学、生物化学、免疫组织化学、Western blotting、RT-PCR等实验技术观察蒙药乳腺-Ⅰ号的治疗作用及蒙药乳腺-Ⅰ号对大鼠乳腺组织中ER,PR和AR在蛋白水平和基因水平的影响。利用2D-DIGE、MALDI-TOF/TOF-MS技术结合生物信息学方法,对蒙药乳腺-Ⅰ号治疗组及对照组大鼠乳腺组织的总蛋白进行双向电泳分离,得到高度重复性的双向凝胶电泳图谱,通过图象分析,得到蒙药乳腺-Ⅰ号治疗组和对照组大鼠乳腺组织中的差异蛋白质图谱,找到两者具有显著性差异的蛋白点,并对这些差异蛋白点进行质谱鉴定,从而为在蛋白水平研究蒙药乳腺-Ⅰ号的作用机制,深入研究与蒙药乳腺-Ⅰ号治疗相关的蛋白质和基因打下了坚实的基础,为今后应用现代科学的方法开发蒙药,提升蒙药研发的技术层次寻找出了一条新的途径。
具体实验结果如下：
1.通过给大鼠肌内注射苯甲酸雌二醇0.5 mg·kg-1·d-1 25d,继续注射孕酮4mg·kg-1·d-1 5d后,乳腺增生大鼠乳头直径较正常对照组大鼠乳头直径明显增宽(P<0.01),血清TC、TG、LDL-c、E2、LH及PRL水平较正常对照组显著增加(P<0.01或P<0.05),FSH水平有增高趋势,P、T水平较正常对照组显著降低(P<0.01或P<0.05),乳腺增生大鼠乳腺组织中ER、PR及AR的表达量较正常对照组显著升高(P<0.01),ER、AR的mRNA表达有显著的增加(P<0.01),PR的mRNA表达明显减少(P<0.01)。乳腺增生大鼠均出现典型的乳腺增生,表现为小叶小管及末梢导管不同程度扩张,上皮细胞增生,导管壁细胞层次增多,多数上皮细胞排列紊乱,向管腔内突出,管腔内有大量脱落的上皮和分泌物：乳腺小叶体积明显增大,分叶多,腺泡腔显著扩张：
2.蒙药乳腺-Ⅰ号治疗组大鼠乳腺小叶小管、末梢导管扩张程度及上皮细胞增生程度较乳腺增生大鼠有所减轻,乳腺小叶体积、腺泡分叶均有所减少,腺泡腔可见轻微扩张.间质纤维组织增生减轻,部分可接近正常大鼠的乳腺腺泡结构。蒙药乳腺-Ⅰ号可显著降低乳腺增生大鼠血清中的TC、TG、LDL-c水平(P<0.01或P<0.05),显著降低乳腺增生大鼠血清中E2及LH水平,显著升高增生大鼠血清中P、T、FSH及PRL水平(P<0.01或P<0.05)：蒙药乳腺-Ⅰ号高剂量可显著降低乳腺增生大鼠乳腺组织中ER、PR及AR蛋白的表达(P<0.05或P<0.01).显著降低乳腺组织中ER、AR的nRNA的表达,升高PR mRNA的表达；
3.对各组大鼠乳腺组织中的总蛋白进行双向电泳分离,得到高度重复性的双向凝胶电泳图谱,通过图象分析,找出正常对照组组与模型组之间差异大于1.3倍的蛋白点43个,其中受到蒙药乳腺-Ⅰ号调节的蛋白点27个；
4.应用质谱和生物信息学技术,对27个蛋白点进行鉴定,其中17种蛋白质被成功鉴定。该17种蛋白质涉及到10类不同的生物学过程,包括代谢、信号转导、细胞骨架和细胞运动、氧化应激、免疫、细胞周期等。
本研究得出以下结论：
1.乳腺增生的发病机制与血清中内分泌激素紊乱、乳腺组织中激素受体的蛋白及基因表达增加密切相关；
2.蒙药乳腺-Ⅰ号可以降低乳腺增生大鼠血清中雌激素水平,升高孕激素水平、改善乳腺增生大鼠体内性激素紊乱的状态；
3.蒙药乳腺-Ⅰ号可调节乳腺增生大鼠乳腺组织ER,PR及AR蛋白的表达及各自mRNA的表达,减轻大鼠乳腺组织增生性损伤；
4.通过注射外源性雌激素联合孕激素诱导的乳腺增生大鼠,其血清血脂代谢出现紊乱,蒙药乳腺-Ⅰ号可以降低实验性乳腺增生大鼠血清TC,TG和LDL-c,调节乳腺增生大鼠的血脂代谢紊乱；
5.利用差异蛋白质组学技术对蒙药乳腺-Ⅰ号干预下的蛋白表达情况进行了研究,通过软件分析得到了27个表达发生显著变化蛋白点；应用质谱技术对蛋白点进行了鉴定,共鉴定出17个差异表达蛋白,这些蛋白分别涉及到代谢、信号转导、细胞骨架和细胞运动、氧化应激、免疫、细胞周期等多种生物学过程。
本研究的创新点：
1.采用给大鼠肌内注射雌激素联合孕激素的方法,建立乳腺增生动物模型,系统地研究了蒙药乳腺-Ⅰ号对大鼠乳腺增生的治疗作用,从内分泌激素和受体两方面初步探讨了其相关的作用机制；
2.运用蛋白质组学技术初步建立了乳腺增生动物模型的血清和乳腺组织蛋白质组学研究技术平台；
3.首次利用蛋白质组学技术,研究乳腺增生动物模型乳腺组织的蛋白质组变化,为乳腺增生症的发病机制的研究提供了新的研究思路和方法；
4.首次采用蛋白质组学方法对蒙药复方制剂的药物机制进行研究,为研究蒙药作用靶点问题提供了崭新的思维模式。
Benign lesions of the breast are far more frequent than malignant ones. Breast hyperplasia is one of these lesions and is also one of the risk factors for breast cancer.The World Health Organization advocates early prevention and detection in order to improve breast cancer outcome, and these measures remain the cornerstone of breast cancer control. However, patients with breast hyperplasia are reluctant to undergo tissue resection because it is painful, often allows recurrence, and does nothing to treat the underlying, causative endocrine imbalance. Instead, multiple applied estrogen or estrogen receptor antagonist agents, including tamoxifen, have been used. Although these drugs can relieve symptoms in patients, they have many side effects and complications, and their use also can lead to endocrine disorders Mongolian medicine plays an important role in Chinese ethnic medicine. But very little scientific evidence exist that support consumption of Mongolian medicine herbal preparations in traditional medicine. So RuXian-Ⅰis only in clinical use in the Affiliated Hospital of Inner Mongolia University for the Nationalities as a traditionally drug, lacks widespread application. RuXian-Ⅰtreatment of breast hyperplasia in 400 patients showed that the cure rate was 98%.But very little scientific evidence exist that support consumption of Mongolian medicine herbal preparations in traditional medicine. Two dimensional difference gel electrophoresis (2D-DIGE) can greatly reduce the inter-gel variation and excessive time/labor costs associated with standard 2-DE and can allow a more accurate qualitative and quantitative analysis. There have been several reports comparing the expression profiles of proteins in breast cancer tissues with those in nontumor breast tissues. However, expression profiles of proteins in breast hyperplasia have not been reported. In order to gain a better insight into the mechanism of RuXian-Ⅰ's efficacy, diagnosis, therapy, outcomes, and prognosis in the breast hyperplasia, and the relation between breast hyperplasia and breast cancer, we used intramuscular estrogen and progesterone to induce rat breast hyperplasia and 2D-DIGE to study the proteins associated with RuXian-Ⅰtreatment. Differentially expressed spots were identified by MALDI-TOF/TOF-MS, and changes in the expression of the proteins of interest were further validated using immunohistochemical and biochemical detection methods.
In this study, we tested the breast-protective effects of RuXian-Ⅰ,in rats with estradiol/progesterone induced breast hyperplasia. Rats were divided into 5 groups:a control group, a model group, a tamoxifen citrate (positive control) group, a RuXian-Ⅰhigh-dose group and a RuXian-Ⅰlow-dose group.As a first step toward the investigation of biomarkers associated with RuXian-Ⅰtreatment, a proteome-wide analysis of rat breast tissue was conducted in this study. First, rat breast hyperplasia was induced by injection with estradiol and progesterone. We used an approach that integrates size-based 2D DIGE, MALDI-TOF/TOF-MS,and bioinformatics to analyze data from the control group, the model group and the RuXian-Ⅰtreatment group.After 2D DIGE, the Cy2, Cy3, and Cy5 channels of each gel were individually imaged, and the images were analyzed using DeCyder 5.0 software.
The main results of this study are as follows:
1.Compared with the model group, the RuXian-Ⅰgroup experienced markedly limited increases in nipple diameter, reduced histopathological changes, and decreased serum estradiol (E2) and luteinizing hormone (LH) levels.RuXian-Ⅰwas increased significantly progesterone (P), testosterone (T) levels and significantly follicle stimulating hormone (FSH),but it did not affect prolactin (PRL) in breast hyperplasia rats at 30 d. RuXian-Ⅰdemonstrated the same treatment effect as tamoxifen citrate for nipple diameter size and histopathological change; however, tamoxifen citrate affected the regulation of serum hormones differently than RuXian-Ⅰ.
2. The RuXian-Ⅰtreatment mechanism may involve decreased expression of estrogen receptor(ER), progesterone receptor (PR), androgen receptors(AR),ER mRNA and AR mRNA in breast hyperplasia tissue. The study showed that protein expression levels of ER, PR and AR in the model group increased relative to the control group (P<0.01).ER, PR and AR protein expression levels in RuXian-Ⅰgroups all decreased significantly compared with the model group (P<0.01)by immunohistochemistry and western blotting. RuXian-Ⅰregulated mRNA expression of ER, PR and AR of sex hormone receptor transcription. The results demonstrated that the mRNA expression of ER and AR increased (P<0.01) and PR mRNA expression decreased (P<0.01) significantly in the model group compared to the control group. RuXian-Ⅰhigh and low dose groups remarkably decreased ER and AR mRNA expression and increased PR mRNA expression. In conclusion, RuXian-Ⅰcould reduce increases in nipple diameter, decrease histopathological changes and adjust regulation of serum sex hormone. This protective effect may be partially mediated through affecting mRNA and protein expression of ER, PR and AR.
3.17 spots corresponding to 16 different gene products were identified by matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF-MS). There are two spots (corresponding to Tpil protein and myosin-4) that are significantly down-regulated in the disease model (ratio<1.3, p<0.01) but increased after treatment with RuXian-Ⅰ.The other 15 spots were significantly up-regulated (ratio>1.3, p<0.01) in the disease model group, but down-regulated after treatment with RuXian-Ⅰ.And two have the opposite change trend.
4.Following protein identification, they were categorized using the PANTHER gene ontology database. The PANTHER classification system grouped the 17 proteins from the mammary glands into 10 major subcategories according to "biological processes",including the immune system process, metabolic process, response to stimulus, transport, et al.
The conclusions of this study are as follows:
1.The pathogenesis of breast hyperplasia is closely related to serum endocrine hormone disorders and hormone receptors gene and protein expression increase in breast tissue;
2.RuXian-Ⅰcan reduce serum estrogen levels, increased progesterone levels, improve the hormone disorder state in the hyperplasia of mammary glands rats;
3. RuXian-Ⅰcan adjust mammary glands ER, PR and AR protein expression and their respective mRNA expression, then treatment of rat mammary gland hyperplasia;
4. Injection of exogenous estrogen and progesterone-induced hyperplasia of mammary glands in rats, serum lipid metabolism in disturbance;
5. RuXian-Ⅰcan reduce serum TC,TG and LDL-c levels and regulate lipid metabolism in hyperplasia of mammary glands rats;
6.RuXian-Ⅰtherapeutic effects of breast hyperplasia related to metabolism, signal transduction, cytoskeleton and cell motility, oxidative stress, immunity, cell cycle and other biological processes;
The creative points of the present study are:
1.Intramuscular injection to rats with estrogen and progesterone used to establish animal models of hyperplasia of mammary glands studied systematically of the RuXian-Ⅰ on the treatment of hyperplasia of mammary glands in rats, from both endocrine hormones and receptors discussed the related Mechanism of action;
2.Initial establishment animal models of breast hyperplasia in serum and breast tissue proteomics technology platform by proteomics technology;
3.The first use of proteomics technology to study animal models of hyperplasia of mammary glands proteome changes in breast tissue for breast hyperplasia in the pathogenesis of the study provides new ideas and methods;
4. Proteomics approach was first introduced to study the Mongolian compound preparation mechanism for the study the problem of Mongolian medicine targets provides a new mode of thinking.
目前关于乳腺癌的蛋白质组学研究报道较多,而乳腺增生症蛋白质组学的相关报道并不多见,通过实验动物建立乳腺增生动物模型,进而对蒙药乳腺-Ⅰ号治疗作用的蛋白质组学研究迄今未见报道。本研究通过采用雌激素联合孕激素肌内注射的方法复制大鼠乳腺增生模型,利用形态学、生物化学、免疫组织化学、Western blotting、RT-PCR等实验技术观察蒙药乳腺-Ⅰ号的治疗作用及蒙药乳腺-Ⅰ号对大鼠乳腺组织中ER,PR和AR在蛋白水平和基因水平的影响。利用2D-DIGE、MALDI-TOF/TOF-MS技术结合生物信息学方法,对蒙药乳腺-Ⅰ号治疗组及对照组大鼠乳腺组织的总蛋白进行双向电泳分离,得到高度重复性的双向凝胶电泳图谱,通过图象分析,得到蒙药乳腺-Ⅰ号治疗组和对照组大鼠乳腺组织中的差异蛋白质图谱,找到两者具有显著性差异的蛋白点,并对这些差异蛋白点进行质谱鉴定,从而为在蛋白水平研究蒙药乳腺-Ⅰ号的作用机制,深入研究与蒙药乳腺-Ⅰ号治疗相关的蛋白质和基因打下了坚实的基础,为今后应用现代科学的方法开发蒙药,提升蒙药研发的技术层次寻找出了一条新的途径。
具体实验结果如下：
1.通过给大鼠肌内注射苯甲酸雌二醇0.5 mg·kg-1·d-1 25d,继续注射孕酮4mg·kg-1·d-1 5d后,乳腺增生大鼠乳头直径较正常对照组大鼠乳头直径明显增宽(P<0.01),血清TC、TG、LDL-c、E2、LH及PRL水平较正常对照组显著增加(P<0.01或P<0.05),FSH水平有增高趋势,P、T水平较正常对照组显著降低(P<0.01或P<0.05),乳腺增生大鼠乳腺组织中ER、PR及AR的表达量较正常对照组显著升高(P<0.01),ER、AR的mRNA表达有显著的增加(P<0.01),PR的mRNA表达明显减少(P<0.01)。乳腺增生大鼠均出现典型的乳腺增生,表现为小叶小管及末梢导管不同程度扩张,上皮细胞增生,导管壁细胞层次增多,多数上皮细胞排列紊乱,向管腔内突出,管腔内有大量脱落的上皮和分泌物：乳腺小叶体积明显增大,分叶多,腺泡腔显著扩张：
2.蒙药乳腺-Ⅰ号治疗组大鼠乳腺小叶小管、末梢导管扩张程度及上皮细胞增生程度较乳腺增生大鼠有所减轻,乳腺小叶体积、腺泡分叶均有所减少,腺泡腔可见轻微扩张.间质纤维组织增生减轻,部分可接近正常大鼠的乳腺腺泡结构。蒙药乳腺-Ⅰ号可显著降低乳腺增生大鼠血清中的TC、TG、LDL-c水平(P<0.01或P<0.05),显著降低乳腺增生大鼠血清中E2及LH水平,显著升高增生大鼠血清中P、T、FSH及PRL水平(P<0.01或P<0.05)：蒙药乳腺-Ⅰ号高剂量可显著降低乳腺增生大鼠乳腺组织中ER、PR及AR蛋白的表达(P<0.05或P<0.01).显著降低乳腺组织中ER、AR的nRNA的表达,升高PR mRNA的表达；
3.对各组大鼠乳腺组织中的总蛋白进行双向电泳分离,得到高度重复性的双向凝胶电泳图谱,通过图象分析,找出正常对照组组与模型组之间差异大于1.3倍的蛋白点43个,其中受到蒙药乳腺-Ⅰ号调节的蛋白点27个；
4.应用质谱和生物信息学技术,对27个蛋白点进行鉴定,其中17种蛋白质被成功鉴定。该17种蛋白质涉及到10类不同的生物学过程,包括代谢、信号转导、细胞骨架和细胞运动、氧化应激、免疫、细胞周期等。
本研究得出以下结论：
1.乳腺增生的发病机制与血清中内分泌激素紊乱、乳腺组织中激素受体的蛋白及基因表达增加密切相关；
2.蒙药乳腺-Ⅰ号可以降低乳腺增生大鼠血清中雌激素水平,升高孕激素水平、改善乳腺增生大鼠体内性激素紊乱的状态；
3.蒙药乳腺-Ⅰ号可调节乳腺增生大鼠乳腺组织ER,PR及AR蛋白的表达及各自mRNA的表达,减轻大鼠乳腺组织增生性损伤；
4.通过注射外源性雌激素联合孕激素诱导的乳腺增生大鼠,其血清血脂代谢出现紊乱,蒙药乳腺-Ⅰ号可以降低实验性乳腺增生大鼠血清TC,TG和LDL-c,调节乳腺增生大鼠的血脂代谢紊乱；
5.利用差异蛋白质组学技术对蒙药乳腺-Ⅰ号干预下的蛋白表达情况进行了研究,通过软件分析得到了27个表达发生显著变化蛋白点；应用质谱技术对蛋白点进行了鉴定,共鉴定出17个差异表达蛋白,这些蛋白分别涉及到代谢、信号转导、细胞骨架和细胞运动、氧化应激、免疫、细胞周期等多种生物学过程。
本研究的创新点：
1.采用给大鼠肌内注射雌激素联合孕激素的方法,建立乳腺增生动物模型,系统地研究了蒙药乳腺-Ⅰ号对大鼠乳腺增生的治疗作用,从内分泌激素和受体两方面初步探讨了其相关的作用机制；
2.运用蛋白质组学技术初步建立了乳腺增生动物模型的血清和乳腺组织蛋白质组学研究技术平台；
3.首次利用蛋白质组学技术,研究乳腺增生动物模型乳腺组织的蛋白质组变化,为乳腺增生症的发病机制的研究提供了新的研究思路和方法；
4.首次采用蛋白质组学方法对蒙药复方制剂的药物机制进行研究,为研究蒙药作用靶点问题提供了崭新的思维模式。
Benign lesions of the breast are far more frequent than malignant ones. Breast hyperplasia is one of these lesions and is also one of the risk factors for breast cancer.The World Health Organization advocates early prevention and detection in order to improve breast cancer outcome, and these measures remain the cornerstone of breast cancer control. However, patients with breast hyperplasia are reluctant to undergo tissue resection because it is painful, often allows recurrence, and does nothing to treat the underlying, causative endocrine imbalance. Instead, multiple applied estrogen or estrogen receptor antagonist agents, including tamoxifen, have been used. Although these drugs can relieve symptoms in patients, they have many side effects and complications, and their use also can lead to endocrine disorders Mongolian medicine plays an important role in Chinese ethnic medicine. But very little scientific evidence exist that support consumption of Mongolian medicine herbal preparations in traditional medicine. So RuXian-Ⅰis only in clinical use in the Affiliated Hospital of Inner Mongolia University for the Nationalities as a traditionally drug, lacks widespread application. RuXian-Ⅰtreatment of breast hyperplasia in 400 patients showed that the cure rate was 98%.But very little scientific evidence exist that support consumption of Mongolian medicine herbal preparations in traditional medicine. Two dimensional difference gel electrophoresis (2D-DIGE) can greatly reduce the inter-gel variation and excessive time/labor costs associated with standard 2-DE and can allow a more accurate qualitative and quantitative analysis. There have been several reports comparing the expression profiles of proteins in breast cancer tissues with those in nontumor breast tissues. However, expression profiles of proteins in breast hyperplasia have not been reported. In order to gain a better insight into the mechanism of RuXian-Ⅰ's efficacy, diagnosis, therapy, outcomes, and prognosis in the breast hyperplasia, and the relation between breast hyperplasia and breast cancer, we used intramuscular estrogen and progesterone to induce rat breast hyperplasia and 2D-DIGE to study the proteins associated with RuXian-Ⅰtreatment. Differentially expressed spots were identified by MALDI-TOF/TOF-MS, and changes in the expression of the proteins of interest were further validated using immunohistochemical and biochemical detection methods.
In this study, we tested the breast-protective effects of RuXian-Ⅰ,in rats with estradiol/progesterone induced breast hyperplasia. Rats were divided into 5 groups:a control group, a model group, a tamoxifen citrate (positive control) group, a RuXian-Ⅰhigh-dose group and a RuXian-Ⅰlow-dose group.As a first step toward the investigation of biomarkers associated with RuXian-Ⅰtreatment, a proteome-wide analysis of rat breast tissue was conducted in this study. First, rat breast hyperplasia was induced by injection with estradiol and progesterone. We used an approach that integrates size-based 2D DIGE, MALDI-TOF/TOF-MS,and bioinformatics to analyze data from the control group, the model group and the RuXian-Ⅰtreatment group.After 2D DIGE, the Cy2, Cy3, and Cy5 channels of each gel were individually imaged, and the images were analyzed using DeCyder 5.0 software.
The main results of this study are as follows:
1.Compared with the model group, the RuXian-Ⅰgroup experienced markedly limited increases in nipple diameter, reduced histopathological changes, and decreased serum estradiol (E2) and luteinizing hormone (LH) levels.RuXian-Ⅰwas increased significantly progesterone (P), testosterone (T) levels and significantly follicle stimulating hormone (FSH),but it did not affect prolactin (PRL) in breast hyperplasia rats at 30 d. RuXian-Ⅰdemonstrated the same treatment effect as tamoxifen citrate for nipple diameter size and histopathological change; however, tamoxifen citrate affected the regulation of serum hormones differently than RuXian-Ⅰ.
2. The RuXian-Ⅰtreatment mechanism may involve decreased expression of estrogen receptor(ER), progesterone receptor (PR), androgen receptors(AR),ER mRNA and AR mRNA in breast hyperplasia tissue. The study showed that protein expression levels of ER, PR and AR in the model group increased relative to the control group (P<0.01).ER, PR and AR protein expression levels in RuXian-Ⅰgroups all decreased significantly compared with the model group (P<0.01)by immunohistochemistry and western blotting. RuXian-Ⅰregulated mRNA expression of ER, PR and AR of sex hormone receptor transcription. The results demonstrated that the mRNA expression of ER and AR increased (P<0.01) and PR mRNA expression decreased (P<0.01) significantly in the model group compared to the control group. RuXian-Ⅰhigh and low dose groups remarkably decreased ER and AR mRNA expression and increased PR mRNA expression. In conclusion, RuXian-Ⅰcould reduce increases in nipple diameter, decrease histopathological changes and adjust regulation of serum sex hormone. This protective effect may be partially mediated through affecting mRNA and protein expression of ER, PR and AR.
3.17 spots corresponding to 16 different gene products were identified by matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF-MS). There are two spots (corresponding to Tpil protein and myosin-4) that are significantly down-regulated in the disease model (ratio<1.3, p<0.01) but increased after treatment with RuXian-Ⅰ.The other 15 spots were significantly up-regulated (ratio>1.3, p<0.01) in the disease model group, but down-regulated after treatment with RuXian-Ⅰ.And two have the opposite change trend.
4.Following protein identification, they were categorized using the PANTHER gene ontology database. The PANTHER classification system grouped the 17 proteins from the mammary glands into 10 major subcategories according to "biological processes",including the immune system process, metabolic process, response to stimulus, transport, et al.
The conclusions of this study are as follows:
1.The pathogenesis of breast hyperplasia is closely related to serum endocrine hormone disorders and hormone receptors gene and protein expression increase in breast tissue;
2.RuXian-Ⅰcan reduce serum estrogen levels, increased progesterone levels, improve the hormone disorder state in the hyperplasia of mammary glands rats;
3. RuXian-Ⅰcan adjust mammary glands ER, PR and AR protein expression and their respective mRNA expression, then treatment of rat mammary gland hyperplasia;
4. Injection of exogenous estrogen and progesterone-induced hyperplasia of mammary glands in rats, serum lipid metabolism in disturbance;
5. RuXian-Ⅰcan reduce serum TC,TG and LDL-c levels and regulate lipid metabolism in hyperplasia of mammary glands rats;
6.RuXian-Ⅰtherapeutic effects of breast hyperplasia related to metabolism, signal transduction, cytoskeleton and cell motility, oxidative stress, immunity, cell cycle and other biological processes;
The creative points of the present study are:
1.Intramuscular injection to rats with estrogen and progesterone used to establish animal models of hyperplasia of mammary glands studied systematically of the RuXian-Ⅰ on the treatment of hyperplasia of mammary glands in rats, from both endocrine hormones and receptors discussed the related Mechanism of action;
2.Initial establishment animal models of breast hyperplasia in serum and breast tissue proteomics technology platform by proteomics technology;
3.The first use of proteomics technology to study animal models of hyperplasia of mammary glands proteome changes in breast tissue for breast hyperplasia in the pathogenesis of the study provides new ideas and methods;
4. Proteomics approach was first introduced to study the Mongolian compound preparation mechanism for the study the problem of Mongolian medicine targets provides a new mode of thinking.
引文
[1]姜军.乳腺增生病：值得重视的临床问题[J].中华乳腺病杂志(电子版),2008,2：13-19.
[2]辛志芳.乳腺增生病的分类和诊治[J].中华乳腺病杂志(电子版),2008,2：6.
[3]曹旭晨译.乳腺痛的病因与治疗//宁连胜方志沂主译.现代乳腺疾病治疗学.2版.北京：人民卫生出版社,2007：26-36.
[4]陈志斌,孟菊萍,韩永彬等.中西医结合治疗乳腺增生病360例[J].中国中西医结合杂志,2003,9(5)：402-403.
[5]杨雪静,毛启新,李鹏.天津市和平区行政事业单位女性乳腺增生病普查情况[J].中国慢性病预防与控制2010,18(1)：94-95
[6]钱晶.乳腺增生病发病现状调查及分析[J].现代中西医结合杂志,2005,14(1)：136-137.
[7]陈毓芬,张树荣,林碧青,等.妇女乳腺疾病相关因素的探讨[J].中国妇幼保健,2001,16(19)：5691.
[8]杨丽.532例乳腺病的病因分析及干预措施[J].首度医学,2006,35.
[9]韩玉洁.“疏肝消核方”治疗乳腺增生病43例临床观察[J].新中医,1990,22：36-38.
[10]张艳,周度金,陈彬,等.核受体超家族及其辅调节子的研究进展[J].局解手术学杂志,2007,96-98.
[11]Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERa-Shc association and Shc pathway activation [J]. MolEndocrinol 2002, 16(1):116-127.
[12]洪素兰,芦锰,张翠英,秦元刚.肝舒乐片对乳腺增生病大鼠性激素受体的影响[J].中医研究,2007,20(4)：12-14.
[13]谈寅飞,王雁玲.雌激素受体信号通路新进展[J]细胞生物学杂志,2004,119-124
[14]雷忻,张育辉,李亚琳.卵巢雌激素受体的研究进展[J].延安大学学报(自然科学版),2004,73-76.
[15]Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERa-Shc association and Shc pathway activation [J]. MolEndocrinol 2002, 16(1):116-127.
[16]Song RX, Barnes CJ, Zhang Z, et al. The role ofShc and insulinlike growth factor1 receptor inmediating the translocation of estrogen receptor alpha to the plasma membrane [J]. Proc NatlAcad SciUSA,2004,101(7):2076-2081.
[17]LOPEZGN, TURCKCW, SCHAUFELEF, et al.Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of P160 coactivator activityn[J].J Biol Chem,2001,276:22177-22182.
[18]王颀,杨剑敏,陈中扬.乳腺增生病//左文述.现代乳腺肿瘤学.2版.济南：山东科学技术出版社,2006,1382-1389.
[19]宁连胜.乳腺增生性改变//李树玲.乳腺肿瘤学.北京：科学技术文献出版社,2000：326-329.
[20]BodianCA, PerzinKH, LattesR, et al. Prognostiesignificaneeofbenign Proliferative breastdisease [J].Caneer,1993,71:3896-3907.
[21]傅西林.乳腺增生性病变//李树玲.乳腺肿瘤学.北京：科学技术文献出版社,2000,73-80.
[22]孙强.乳腺癌的早期诊断[J].实用医学杂志,2007,23(1)：1-3.
[23]阚秀.乳腺组织学分类[J].诊断病理学杂志,2004,(3)：26.
[24]Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease [J]. N Engl J Med,1985,312:146-51.
[25]Silverberg SG, Masood S. Principles and Practice of Surgical Pathology and Cytopathology [M], Third Edition. New York:Churchill-Livingstone Inc,1997, 575-673.
[26]杨举伦,刘大荣,蔡学敏,等H-ras, c-erbB-2, p53蛋白在乳腺增生病中的表达及意义[J].中华病理学杂志,1999,28(6)：450.
[27]London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer [J], JAMA,1992,267:941-944.
[28]刘胜春,吴凯南,厉红元.血管生成在乳腺非典型增生及癌变过程中的作用[J].中国肿瘤临床,1998,25(6)：421-424.
[29]卫洪波,陈登庭,叶飞,等.乳腺癌与纤维囊性乳腺病相关性探讨[J].洛阳医专学报,1999,17(7)：17-19.
[30]Moyano, J.V.;Evans, J.R.;Chen, F.;Lu, M.;Werner, M.E.;Yehiely, F.;Diaz, L.K.; Turbin, D.; Karaca, G.; Wiley, E.; et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest.2006,116,261-270.
[31]Launay, N.;Goudeau, B.;Kato, K.;Vicart, P.;Lilienbaum, A. Cell signaling pathways to alpha B-crystallin following stresses of the cytoskeleton. Exp. Cell. Res.2006,312, 3570-3584.
[32]洪和平,程伏林.三苯氧胺不同用药方法治疗乳腺腺病[J].中国综合临床,2004,20(1)：59-60.
[33]Semiglazov VF, Maksimov SIa, Bulgatova EA, Meshkova IE, Chepik OF, Berstein LM. Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen [J]. Vopr Onkol.2003,49,198-204.
[34]朱昭远.三苯氧胺、维生素E联合治疗乳腺囊性增生症868例观察[J].临床医学杂志,2002,6(2)：1421.
[35]董玉华.甲磺酸嗅隐亭片在抑制产后乳汁分泌中的应用[J].护理与健康,2009,8(2)：158-158.
[36]Cirpan T, Iscan O, Terek MC, et al. Proliferative effects of different hormone regimens on mammary glands in ovariectomized rats [J]. Eur J Gynaecol Oncol.2006; 27(3):256-61.
[37]马彩云,孔卫平.乳块消治疗乳腺增生病720例[J].实用中医内科杂志,2003,17(4)：325.
[38]鲁德萍,李彩玲,季晓更.消症散治疗乳腺囊性增生的临床观察[J].河南大学学报(医学科学版),2003,22(3)：23.
[39]Chen X, Zhang J G, Liu Y. Experimental study on ruxian pill I in treating mammary gland hyperplasia rabbits [J]. Zhong guo Zhong Xi Yi Jie He Za Zhi,2007,27 (9):822.
[40]Chen SS, Guo QS, Jin R, et al. Effects of Rukuaixiao decoction on hyperplasia of mammary gland in rats [J]. Zhong guo ZhongYao Za Zhi,2007,32 (12):1198.
[41]何毕力格,包英妹,包玉英.蒙药八味狼毒散外敷治疗乳腺增生病50例[J].中国民族医药杂志,1996,23.
[42]富玉兰,包文凯.蒙药离子透入治疗乳腺增生29例临床观察[J].中国民族民间医药杂志,2001,339.
[43]脑日布,杨迅,李英.蒙药治疗乳腺增生63例[J],中国民族医药杂志,2006,33.
[44]额都,秀兰,鲍路明.用乳腺Ⅰ号治疗乳腺囊性增生病400例疗效观察[J].内蒙古民族大学学报,2005,704-705.
[45]Arciero C, Somiari SB, Shriver CD, et al. Functional relationship and gene ontology classification of breast cancer biomarkers [J]. Int J Biol Markers,2003,18 (4):241-272.
[46]Fields S. Proteomics. Proteomics in genomeland. Science,2001,291(5507):1221-1224.
[47]O'Farrell P H. High resolution two-dimensional electrophores is of proteins [J]. J Biol Chem,1975,250:4007-4021.
[48]Wulfkuhle J D, Sgroi D C, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ [J].Cancer Res,2002,62(22):6740-6749.
[49]Somiari R I, Sullivan A, Russell S, et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast[J]. Proteomics,2003,3(10):1863-1873.
[50]Bisca A, D'Ambrosio C, Scaloni A, et al. Proteomic evaluation of core biopsy specimens from breast lesions[J]. Cancer Lett,2004,204(1):79-86.
[51]Somiari R I, Sullivan A, Russell S, et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast[J]. Proteomics,2003,3(10):1863-1873
[52]Somiari R I, Somiari S, Russell S, et al. Proteomics of breast carcinoma[J]. J Chromatogr B,2005,815(1-2):215-225.
[53]Goncalves A, Esterni B, Bertucci F, et al. Postope rative serum proteomic profiles may predictm etastatic re lapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy[J]. Oncogene,2006,25(7):981-989.
[54]Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer:principles and potential clinical applications[J]. Mol Cell Proteomics,2006,5(10):1772-1786.
[55]Czerwenka K F, Manavi M, Hosmann J, et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue[J]. Cancer Detect Prev, 2001,25 (3):268-279.
[56]Cowherd S M, Espina V A, Petricoin E F 3rd, et al. Proteomic analysis of human breast cancer tissue with laser-capture microdissectionandreverse- phaseproteinm-icroarrays[J]. Clin Breast Cancer,2004,5(5):385-392.
[57]Zang L, Palmer Toy D, Hancock W S, et al. Proteomic analysisof ductal carcinoma of the breast using laser capturemicrodissection, LC-MS, and 16O/18O isotopic labeling [J]. J Proteome Res,2004,3(3):604-612.
[58]Sauter ER, Shan S, Hewett JE, et al. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS [J]. Int J Cancer,2005,114(5):791-796.
[59]Strong R, Nakan ish iT, Ross D, et al. Alterations in the mitochondrial proteome of adriamyc in resistant MCF-7 breast cancer cells [J]. J Proteome Res,2006,5(9): 2389-2395.
[60]张丽军,谭丁桃.乳腺癌蛋白质组研究进展[J].生命科学,2007,19(5)：512-517.
[61]Adkins J N, Varnum S M, Auberry K J, et al.Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry [J]. Mol Cell Proteomics,2002,1(12):947-955.
[62]Andersom NL, Anderson NG.The human plasma proteome:history, character, and diagnostic prospects. Mol Cell Proteomics,2002,1:845-867.
[63]Thadikkaran L, Siegenthaler M A, Crettaz D, et al. Recent advances in blood-related proteomics [J].Proteomics,2005,5(12):3019-3034.
[64]Omenn GS, States DJ, AdamskiM, et al. Overview of the HUPO Plasma Proteome Project:Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core datasets of 3020 proteins and a publicly-available database.Proteomics,2005,5:3226-3245.
[65]刘士君.乳腺通治疗小鼠乳腺增生性病变的病理组织学观察研究.辽宁中医杂志,2003,30(5)：422
[66]Bjorhall K, Miliotis T, Davidsson P, et al. Comparison of different depletion strategies for improved resolution in protiomic analysis of human serum samples. Proteomics, 2005,5:307-317.
[67]Chromy B A, Gonzales A D, Perkins J, et al. Proteomic analysis of human serum by Two-dimentional Differential Gel Electrophoresis after Depletion of High-Abundant Proteins. J Proteome Res,2004,3:112021127.
[68]Srisomsap C, Sawangareetrakul P. et al. Proteomic analysis of cholangiocar-cinoma cell line. Proteomics,2004,4:1135-1144.
[69]Hinerfeld D, Innamorati D, Pirro J,et al. Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple mammalian species. J Biomol Tech,2005,15:184-190.
[70]Huang L, Harvie G, Feitels on JS, et al.Immunoaffinity separati on of plasma proteins by IgY microbeads:Meeting the needs of proteomic sample preparati on and analysis. Proteomics,2005,5:3314-3328.
[71]Ahmed N, Barker G, KT Olival, et al. An app r oach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Pr oteomics,2004,3: 1980-1987.
[72]王建东,任艳,夏季,等.小鼠血浆去除白蛋白前后的双向凝胶电泳分析中华实验外科杂志,2004,1374-1375.
[73]Fu Q, Gamham CP, Elliott ST, et al. A robust,streamlined,and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophresis[J]. Proteomics,2005,5(10):2656.
[74]潘俊,罗晓阳,陈海泉.乙醇沉淀法去除人血清清蛋白的实验研究,2008,2110(10)：34-1039.
[75]Alpert AJ, Shukla AK. Precipitation of lagre, high-abundance proteins from serum with organic solvents. ABRF 2003:Translating biology using proteomics and functional genomics. Poster no. P111-W.
[76]Race, et al. The determination of blood proteins by acid-acetone [J], Biochem. J.1932, 26,1571-1575.
[77]Levine S. Solubilization of 'Jovine albumin in nonaqueous media [J]. Arch. Biochem. Biophys.1954,50,515-517.
[78]Chen Y, Lin S, Yeh YY, et al. A modified p rotein preci pitation procedure for efficient removal of albumin from serum [J].Electrophoresis,2005,26:2117-2127.
[79]邱宗荫,尹一兵等.临床蛋白质组学[M].北京：科学出版社.2008,165-169.
[80]张雪群,姜颖,厉有名,等.人血浆低丰度蛋白伏击方法的研究进展.中华医学检验杂志[J].2006,29(10)：947-950.
[81]Wang K, Johnson A, Obradovic M, et al. TSE clearance during plasma products separation process by Gradiflow(TM) [J].Biologicals,2005,33:87-94.
[82]Cho S Y, Lee E, Lee J S, et al. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics,2005,5: 3386-3396.
[83]Wildgruber R, Harder A, Obermaier C, et al. Towards higher resolution: Two-dimentional electrophresis of saccharomyces cerevisiae proteins using overlapping narrow immobilized PH gradients [J]. Electrophoresis,2000,21:2610-2616.
[84]Fountoulakis M, Juranville JF, JiangL, et al. Depletion of the abundance plasma proteins. Amino Acids[J],2004,27:249-259.
[85]Moritz RL, Clipp ingdale AB, Kapp EA, et al. Application of 2-D free-flow electrophoresis/RP-HPLC for proteomic analysis of human plasma depleted of multihigh-abundance proteins [J]. Proteomics,2005,5:3402-3413.
[86]Tang H, Ali-Khan N, Echan LA, et al. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes [J]. Proteomics,2005,5:3329-3342.
[87]Bocchinfuso WP, lindzey JK, Hewitt SC. Induction of mammary gland development in estrogen receptor-alpha knockout mice [J]. Endocrinology,2000,141:2982-2994.
[88]Thomas E. Rohan, Abdissa Negassa, Rowan T.et al. Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease [J]. Cancer Epidemiology, Biomarkers & Prevention,2008,17:2337-2343.
[89]Carolyn J. Crandall, Arun Karlamangla, et al. Association of New-Onset Breast Discomfort with an Increase in Mammographic Density During Hormone Therapy [J]. Arch Intern Med,2006,166:1578-1584.
[90]Conner P. Breast response to menopausal hormone therapy-aspects on proliferation [J], apoptosis and mammographic density [J]. Ann,2007,39:28-41.
[91]饶金才,李兰珍,陈云生,等.乳腺增生病动物模型的复制及病理类型[J].中国病理生理杂志,1992,8(6)：671-672.
[92]林成仁,王敏,石体仁,等.乳腺增生病动物模型的建立及机理研究[J].中国中西医结合杂志,1997,17：270-272.
[93]余望贻,姜海斌,孟琼,等.乳腺增生病动物模型的实验研究[J].中国实验动物学报,2004,12(4)：25-238
[94]田国富.乳腺癌现代非手术治疗[M].科学技术文献出版社,2008,9.
[95]马南花,黎宗强,覃坚,等.雌性食蟹猴生理月经周期中雌激素变化与血脂水平关系的研究[J].广西医科大学学报,2008,25(3)：390-391
[96]冯力,张远慧,吴赛珠,等.不同剂量雌激素对去势雌兔血脂代谢的影响[J]第一军医大学学报,1998,121-122.
[97]Xia Zhang, Jei-Jun Jiao, Bhagu R. Regulation of human apolipoprotein A-1 gene expression by equine estrogens [J]. J Lipid Res,2001,42:1789-1801.
[98]Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer [J]. Cancer Treat Rev,2009, 35(2):175-184.
[99]Masteikova R, Muselik J, Bernatoniene J, et al. Antioxidant activity of tinctures prepared from hawthorn fruits and motherwort herb [J]. Ceska a Slovenska Farmacie, 2008,57:35-38.
[100]Lee MJ, Lee HS, Park SD, et al. Leonurus sibiricus herb extract suppresses oxidative stress and ameliorates hypercholesterolemia in C57BL/6 mice and TNF-alpha induced expression of adhesion molecules and lectin-like oxidized LDL receptor-1 in human umbilical vein endothelial cells [J]. Biosci, Biotech, Biochem,2010,74,279-284.
[101]陈承祺.乳腺增生病与内分泌激素的变化[J].标记免疫分析与临床,1999,6(2)：130-132.
[102]Fink G. Gonadotropin secretion and its control [J]. The Physiology of Reproduction, 1988,1349-1377.
[103]Ben-Jonathan N. Regulation of prolactin secretion. Ed. H Imura. New York:Raven Press.The Pituitary Gland,1994,261-283.
[104]林惠,郑登滋,胡励军.乳腺小叶增生与性腺轴平衡紊乱[J].中国医药学报,2000,78-79.
[105]J E Sanchez-Criado, J Martin de las Mulas, C Bellido. Gonadotrope oestrogen receptor-and-β and progesterone receptor immunoreactivity after ovariectomy and exposure to oestradiol benzoate, tamoxifen or raloxifene in the rat:correlation with LH secretion [J]. J Endocrinol,2005 184:59-68.
[106]Jose C Garrido-Gracia, Ana Gordon, Carmina Bellido.The integrated action of oestrogen receptor isoforms and sites with progesterone receptor in the gonadotrope modulates LH secretion:evidence from tamoxifen-treated ovariectomized rats [J]. J. Endocrinol,2007,193:107-119.
[107]Gill-Sharma M K, Gopalkrishnan K, Balasinor N, et al. Effects of tamoxifen on the fertility of male rats. Journal of Reproduction and Fertility,1993,99:395-402.
[108]Sijie Li, Bing Han, Guojin Liu. Immunocytochemical Localization of Sex Steroid Hormone Receptors in Normal Human Mammary Gland [J]. J Histochem and Cytochem,2010,58 (6):509-515.
[109]Lawson JS, Field AS, Tran DD. Breast cancer Incidence and estrogen receptor alpha in normal mammary tissue -an epidemiologic study among JapaneseWomen in Japan and Hawaii[J]. Int J Cancer,2002,97(5):685-687.
[110]Shyamala G, Chou YC, Louie SG. Cellular expression of estrogen and Progesterone receptors in mammary glands:regulation by hormones, development and aging [J]. Steroid Biochem Mol Biol,2002,80(2):137-148.
[111]Jennifer R. Wood, Varsha S. Likhite, Margaret A. Loven, et al. Allosteric Modulation of Estrogen Receptor Conformation by Dfferent Estrogen Response Elements[J]. Mol. Endocrinol,2001,15:1114-1120
[112]Savouret JF, Bailly A, Misrahi M, auch C, Redeuilh G,Chauchereau A. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene [J]. EMBO J,1991,10:1875-1883
[113]Hyun-Jung Kim, Xiaojiang Cui, Susan G. Hilsenbeck. Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer [J]. Clin. Cancer Res,2006,12:1013-1018.
[114]Schiff R, Massarweh SA, Shou J. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res,2004,10:331S-336S.
[115]Bardou VJ, Arpino G. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J]. J Clin Onco,2003,21(10):1973-1979.
[116]S. Park, H. Park, S. Choi. Expression of Androgen Receptor in Breast Cancer [J]. Cancer Res,2009,69:4156-4161.
[117]De Abreu F B, Pirolo L J, Canevari Rde A, et al. Shorter CAG Repeat in the AR Gene is Associated with Atypical Hyperplasia and Breast Carcinoma [J]. Anticancer Res, 2007,27:1199-1205
[118]Grant Buchanan, Stephen N. Birrell, Amelia A. Peters. Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate [J]. Cancer Res,2005,65:8487-8496.
[119]钱小红,贺福初等译,蛋白质组学从序列到功能,2002：39.
[120]M. Fountoulakis J.-F.Juranville,L.Jiang.Depletion of the high-abundance plasma proteins[J]. Amino Acids,2004,27:249-259
[121]Chertov O, Biragyn A, Kwak L W. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry[J].Proteomics,2004,4,1195-1203
[122]Craig A,Sidaway J,Holmes E,et al. Systems toxicology:integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat [J].J Proteome Res 2006,5,1586-1601
[123]Yan JX, Wait R, Berkelman T, Harry RA. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry [J].Electrophoresis,2000,21, 3666-3672.
[124]Tang WQ, Deng ZP, Oses-Prieto A,et al.Proteomics Studies of Brassinosteroid Signal Transduction Using Prefractionation and Two-dimensional DIGE [J].Mol.Cell. Proteomics,2008,7:728-738
[125]Lowery JT, Byers T, Kittelson J, et al.Differential expression of prognostic biomarkers between interval and screen-detected breast cancers:does age or family history matter? [J].Breast Cancer Res Treat.2011 Mar 24.
[126]Petricoin E F,Liot ta L A. Proteomic analysis at the bedside:early detection of cancer [J]. Trends Biotechnol,2002,20 (12 Sup2pl):S30-S34.
[127]Sauter ER, Zhu W, Fan XJ, et al. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer [J]. Br J Cancer,2002,86 (9):1440-1443.
[128]Luftner D, Possinger K. Nuclear mat rix proteins as biomarkers for breast cancer[J]. Expert Rev Mol Diagn,2002,2(1):23-31.
[129]Hamler RL, Zhu K, Buchanan NS, et al.A two-dimensional liquidphase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification[J]. Proteomics,2004,4(3):562-577.
[130]Chen ST, Pan TL, Tsai YC, et al. Proteomics reveals protein profile changes in doxorubicin-treated MCF27 human breast cancer cells[J]. Cancer Lett,2002, 181(1)95-107.
[131]Rui Z, Jian Guo J, Yuan-Peng T, et al. Use of serological proteomic met hods to find biomarkers associated wit h breast cancer [J]. Proteomics,2003,3 (4):433-439.
[132]Ahn SH, Sawada H, Ro JY, et al. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp. Metastasis[J].1997,15:151-156.
[133]Mulla A, Christian HC, Solito E et al. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma[J]. Clin Endocrinol (Oxf),2004,60:107-119.
[134]Shen D, Nooraie F, Elshimali Y,et al. Decreased expression of annexin Al is correlated with breast cancer development and progression as determined by a tissue microarray analysis [J]. Hum. Pathol,2006,37:1583-1591.
[135]Alldridge LC, Harris HJ, Plevin R, et al. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway [J]. J. Biol. Che,1999,274,37620-37628.
[136]Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1[J]. J. Steroid Biochem. Mol. Biol.2000,74:311-317.
[137]Estrogen-1 nduced reactive oxygen species-mediated signalings contribute to breast cancer [J].Biochim Biophys Acta.2011 Jan; 1815(1):115-133.
[138]Mobley JA, Brueggemeier RW, et al. Brueggemeier estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer [J]. Carcinogenesis 2004,25,3-9.
[139]Sastre-Serra J. Valle A, Company MM, et al.Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer [J]. Free Radic. Biol. Med. 2010,48,506-512.
[140]Marta W, Urszula KK. Cytoprotective action of 17β-oestradiol against iron-Ⅰ nduced hepatic oxidative stress in vitro [J]. Bull Vet. Inst. Pulawy,2010,54:259-263.
[141]Mense SM, Remotti F, Bhan A, et al. Estrogen-Ⅰ nduced breast cancer:alterations in breast morphology and oxidative stress as a function of estrogen exposure [J]. Toxicol Appl. Pharmacol.2008,232:78-85.
[142]Parmar H, Melov S, Samper E, et al. Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase [J]. Breast 2005,14:256-263.
[143]Kim SU, Hwang CN, Sun HN, et al. Peroxiredoxin I is an indicator of microglia activation and protects againsthydrogen peroxide-mediatedmicroglial death [J]. Biol. Pharm. Bull.2008,31:820-825.
[144]Immenschuh S.; Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation [J]. Antioxid Redox Signal.2005,7:768-777.
[145]Lee YM, Park SH, Shin DI et al. Oxidative modification of peroxiredoxin is associated with drug-Ⅰ nduced apoptotic signaling in experimental models of Parkinson disease[J]. J. Biol. Chem.2008,283:9986-9998.
[146]Noh D Y, Ahn S J, Lee R A, Overexpression of peroxiredoxin in human breast caneer[J]. Antcancer Res,2001,21(3B):2085-2090.
[147]Karihtala P,Mantyniemi A,Kang S W,et al. Peroxiredoxins in breast carcinoma [J].Clin Cancer Res,2003,9(9):3418-3424.
[148]Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases [J]. Annu. Rev. Pharmacol Toxicol.2005,45:51-88.
[149]Meiers I, Shanks JH. Bostwick DG.Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer:review 2007[J]. Pathology 2007,39:299-304.
[150]Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis [J]. Virchows. Arch.2007,450:637-642.
[151]McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy [J]. Oncogene 2006,25:1639-1648.
[152]Parcellier A, Schmitt E, Brunet M,et al. Small heat shock proteins HSP27 and a B-crystallin:cytoprotective and oncogenic functions [J]. Antioxid Redox Signal.2005, 7:404-413.
[153]周英,文海泉.热休克蛋白27在皮肤基底细胞癌和鳞状细胞癌中的表达[J].中华皮肤科杂志.2001,34(5)：381.
[154]O'Neill AP, Shaaban MA, West RC, et al. Inereasedriskofmalignant Progression in benign Proliferating breast lesions defined by expression of heatshoek Protein 27[J]. Br J Caneer.2004.90(1):182-188.
[155]Ahmad MF, Raman B, Ramakrishna T, Rao Ch M. Effect of phosphorylation on alpha B - crystallin:differences in stability, subunit exchange and chaperone activity of homo and mixed oligomers of alpha B - crystallin and its phosphorylation -mimicking mutant [J]. J.Mol. Biol.2008,375,1040-1051.
[156]Kamradt, M.C.; Chen, F.; Sam, S.; Cryns, V.L.The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J. Biol. Chem.2002,277,38731-38736.
[157]Sitterding SM, Wiseman W R, Schiller C L, et al. AlphaB-crystallin:a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann. Diagn. Pathol.2008,12(1), 33-40.
[2]辛志芳.乳腺增生病的分类和诊治[J].中华乳腺病杂志(电子版),2008,2：6.
[3]曹旭晨译.乳腺痛的病因与治疗//宁连胜方志沂主译.现代乳腺疾病治疗学.2版.北京：人民卫生出版社,2007：26-36.
[4]陈志斌,孟菊萍,韩永彬等.中西医结合治疗乳腺增生病360例[J].中国中西医结合杂志,2003,9(5)：402-403.
[5]杨雪静,毛启新,李鹏.天津市和平区行政事业单位女性乳腺增生病普查情况[J].中国慢性病预防与控制2010,18(1)：94-95
[6]钱晶.乳腺增生病发病现状调查及分析[J].现代中西医结合杂志,2005,14(1)：136-137.
[7]陈毓芬,张树荣,林碧青,等.妇女乳腺疾病相关因素的探讨[J].中国妇幼保健,2001,16(19)：5691.
[8]杨丽.532例乳腺病的病因分析及干预措施[J].首度医学,2006,35.
[9]韩玉洁.“疏肝消核方”治疗乳腺增生病43例临床观察[J].新中医,1990,22：36-38.
[10]张艳,周度金,陈彬,等.核受体超家族及其辅调节子的研究进展[J].局解手术学杂志,2007,96-98.
[11]Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERa-Shc association and Shc pathway activation [J]. MolEndocrinol 2002, 16(1):116-127.
[12]洪素兰,芦锰,张翠英,秦元刚.肝舒乐片对乳腺增生病大鼠性激素受体的影响[J].中医研究,2007,20(4)：12-14.
[13]谈寅飞,王雁玲.雌激素受体信号通路新进展[J]细胞生物学杂志,2004,119-124
[14]雷忻,张育辉,李亚琳.卵巢雌激素受体的研究进展[J].延安大学学报(自然科学版),2004,73-76.
[15]Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERa-Shc association and Shc pathway activation [J]. MolEndocrinol 2002, 16(1):116-127.
[16]Song RX, Barnes CJ, Zhang Z, et al. The role ofShc and insulinlike growth factor1 receptor inmediating the translocation of estrogen receptor alpha to the plasma membrane [J]. Proc NatlAcad SciUSA,2004,101(7):2076-2081.
[17]LOPEZGN, TURCKCW, SCHAUFELEF, et al.Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of P160 coactivator activityn[J].J Biol Chem,2001,276:22177-22182.
[18]王颀,杨剑敏,陈中扬.乳腺增生病//左文述.现代乳腺肿瘤学.2版.济南：山东科学技术出版社,2006,1382-1389.
[19]宁连胜.乳腺增生性改变//李树玲.乳腺肿瘤学.北京：科学技术文献出版社,2000：326-329.
[20]BodianCA, PerzinKH, LattesR, et al. Prognostiesignificaneeofbenign Proliferative breastdisease [J].Caneer,1993,71:3896-3907.
[21]傅西林.乳腺增生性病变//李树玲.乳腺肿瘤学.北京：科学技术文献出版社,2000,73-80.
[22]孙强.乳腺癌的早期诊断[J].实用医学杂志,2007,23(1)：1-3.
[23]阚秀.乳腺组织学分类[J].诊断病理学杂志,2004,(3)：26.
[24]Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease [J]. N Engl J Med,1985,312:146-51.
[25]Silverberg SG, Masood S. Principles and Practice of Surgical Pathology and Cytopathology [M], Third Edition. New York:Churchill-Livingstone Inc,1997, 575-673.
[26]杨举伦,刘大荣,蔡学敏,等H-ras, c-erbB-2, p53蛋白在乳腺增生病中的表达及意义[J].中华病理学杂志,1999,28(6)：450.
[27]London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer [J], JAMA,1992,267:941-944.
[28]刘胜春,吴凯南,厉红元.血管生成在乳腺非典型增生及癌变过程中的作用[J].中国肿瘤临床,1998,25(6)：421-424.
[29]卫洪波,陈登庭,叶飞,等.乳腺癌与纤维囊性乳腺病相关性探讨[J].洛阳医专学报,1999,17(7)：17-19.
[30]Moyano, J.V.;Evans, J.R.;Chen, F.;Lu, M.;Werner, M.E.;Yehiely, F.;Diaz, L.K.; Turbin, D.; Karaca, G.; Wiley, E.; et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest.2006,116,261-270.
[31]Launay, N.;Goudeau, B.;Kato, K.;Vicart, P.;Lilienbaum, A. Cell signaling pathways to alpha B-crystallin following stresses of the cytoskeleton. Exp. Cell. Res.2006,312, 3570-3584.
[32]洪和平,程伏林.三苯氧胺不同用药方法治疗乳腺腺病[J].中国综合临床,2004,20(1)：59-60.
[33]Semiglazov VF, Maksimov SIa, Bulgatova EA, Meshkova IE, Chepik OF, Berstein LM. Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen [J]. Vopr Onkol.2003,49,198-204.
[34]朱昭远.三苯氧胺、维生素E联合治疗乳腺囊性增生症868例观察[J].临床医学杂志,2002,6(2)：1421.
[35]董玉华.甲磺酸嗅隐亭片在抑制产后乳汁分泌中的应用[J].护理与健康,2009,8(2)：158-158.
[36]Cirpan T, Iscan O, Terek MC, et al. Proliferative effects of different hormone regimens on mammary glands in ovariectomized rats [J]. Eur J Gynaecol Oncol.2006; 27(3):256-61.
[37]马彩云,孔卫平.乳块消治疗乳腺增生病720例[J].实用中医内科杂志,2003,17(4)：325.
[38]鲁德萍,李彩玲,季晓更.消症散治疗乳腺囊性增生的临床观察[J].河南大学学报(医学科学版),2003,22(3)：23.
[39]Chen X, Zhang J G, Liu Y. Experimental study on ruxian pill I in treating mammary gland hyperplasia rabbits [J]. Zhong guo Zhong Xi Yi Jie He Za Zhi,2007,27 (9):822.
[40]Chen SS, Guo QS, Jin R, et al. Effects of Rukuaixiao decoction on hyperplasia of mammary gland in rats [J]. Zhong guo ZhongYao Za Zhi,2007,32 (12):1198.
[41]何毕力格,包英妹,包玉英.蒙药八味狼毒散外敷治疗乳腺增生病50例[J].中国民族医药杂志,1996,23.
[42]富玉兰,包文凯.蒙药离子透入治疗乳腺增生29例临床观察[J].中国民族民间医药杂志,2001,339.
[43]脑日布,杨迅,李英.蒙药治疗乳腺增生63例[J],中国民族医药杂志,2006,33.
[44]额都,秀兰,鲍路明.用乳腺Ⅰ号治疗乳腺囊性增生病400例疗效观察[J].内蒙古民族大学学报,2005,704-705.
[45]Arciero C, Somiari SB, Shriver CD, et al. Functional relationship and gene ontology classification of breast cancer biomarkers [J]. Int J Biol Markers,2003,18 (4):241-272.
[46]Fields S. Proteomics. Proteomics in genomeland. Science,2001,291(5507):1221-1224.
[47]O'Farrell P H. High resolution two-dimensional electrophores is of proteins [J]. J Biol Chem,1975,250:4007-4021.
[48]Wulfkuhle J D, Sgroi D C, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ [J].Cancer Res,2002,62(22):6740-6749.
[49]Somiari R I, Sullivan A, Russell S, et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast[J]. Proteomics,2003,3(10):1863-1873.
[50]Bisca A, D'Ambrosio C, Scaloni A, et al. Proteomic evaluation of core biopsy specimens from breast lesions[J]. Cancer Lett,2004,204(1):79-86.
[51]Somiari R I, Sullivan A, Russell S, et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast[J]. Proteomics,2003,3(10):1863-1873
[52]Somiari R I, Somiari S, Russell S, et al. Proteomics of breast carcinoma[J]. J Chromatogr B,2005,815(1-2):215-225.
[53]Goncalves A, Esterni B, Bertucci F, et al. Postope rative serum proteomic profiles may predictm etastatic re lapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy[J]. Oncogene,2006,25(7):981-989.
[54]Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer:principles and potential clinical applications[J]. Mol Cell Proteomics,2006,5(10):1772-1786.
[55]Czerwenka K F, Manavi M, Hosmann J, et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue[J]. Cancer Detect Prev, 2001,25 (3):268-279.
[56]Cowherd S M, Espina V A, Petricoin E F 3rd, et al. Proteomic analysis of human breast cancer tissue with laser-capture microdissectionandreverse- phaseproteinm-icroarrays[J]. Clin Breast Cancer,2004,5(5):385-392.
[57]Zang L, Palmer Toy D, Hancock W S, et al. Proteomic analysisof ductal carcinoma of the breast using laser capturemicrodissection, LC-MS, and 16O/18O isotopic labeling [J]. J Proteome Res,2004,3(3):604-612.
[58]Sauter ER, Shan S, Hewett JE, et al. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS [J]. Int J Cancer,2005,114(5):791-796.
[59]Strong R, Nakan ish iT, Ross D, et al. Alterations in the mitochondrial proteome of adriamyc in resistant MCF-7 breast cancer cells [J]. J Proteome Res,2006,5(9): 2389-2395.
[60]张丽军,谭丁桃.乳腺癌蛋白质组研究进展[J].生命科学,2007,19(5)：512-517.
[61]Adkins J N, Varnum S M, Auberry K J, et al.Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry [J]. Mol Cell Proteomics,2002,1(12):947-955.
[62]Andersom NL, Anderson NG.The human plasma proteome:history, character, and diagnostic prospects. Mol Cell Proteomics,2002,1:845-867.
[63]Thadikkaran L, Siegenthaler M A, Crettaz D, et al. Recent advances in blood-related proteomics [J].Proteomics,2005,5(12):3019-3034.
[64]Omenn GS, States DJ, AdamskiM, et al. Overview of the HUPO Plasma Proteome Project:Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core datasets of 3020 proteins and a publicly-available database.Proteomics,2005,5:3226-3245.
[65]刘士君.乳腺通治疗小鼠乳腺增生性病变的病理组织学观察研究.辽宁中医杂志,2003,30(5)：422
[66]Bjorhall K, Miliotis T, Davidsson P, et al. Comparison of different depletion strategies for improved resolution in protiomic analysis of human serum samples. Proteomics, 2005,5:307-317.
[67]Chromy B A, Gonzales A D, Perkins J, et al. Proteomic analysis of human serum by Two-dimentional Differential Gel Electrophoresis after Depletion of High-Abundant Proteins. J Proteome Res,2004,3:112021127.
[68]Srisomsap C, Sawangareetrakul P. et al. Proteomic analysis of cholangiocar-cinoma cell line. Proteomics,2004,4:1135-1144.
[69]Hinerfeld D, Innamorati D, Pirro J,et al. Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple mammalian species. J Biomol Tech,2005,15:184-190.
[70]Huang L, Harvie G, Feitels on JS, et al.Immunoaffinity separati on of plasma proteins by IgY microbeads:Meeting the needs of proteomic sample preparati on and analysis. Proteomics,2005,5:3314-3328.
[71]Ahmed N, Barker G, KT Olival, et al. An app r oach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Pr oteomics,2004,3: 1980-1987.
[72]王建东,任艳,夏季,等.小鼠血浆去除白蛋白前后的双向凝胶电泳分析中华实验外科杂志,2004,1374-1375.
[73]Fu Q, Gamham CP, Elliott ST, et al. A robust,streamlined,and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophresis[J]. Proteomics,2005,5(10):2656.
[74]潘俊,罗晓阳,陈海泉.乙醇沉淀法去除人血清清蛋白的实验研究,2008,2110(10)：34-1039.
[75]Alpert AJ, Shukla AK. Precipitation of lagre, high-abundance proteins from serum with organic solvents. ABRF 2003:Translating biology using proteomics and functional genomics. Poster no. P111-W.
[76]Race, et al. The determination of blood proteins by acid-acetone [J], Biochem. J.1932, 26,1571-1575.
[77]Levine S. Solubilization of 'Jovine albumin in nonaqueous media [J]. Arch. Biochem. Biophys.1954,50,515-517.
[78]Chen Y, Lin S, Yeh YY, et al. A modified p rotein preci pitation procedure for efficient removal of albumin from serum [J].Electrophoresis,2005,26:2117-2127.
[79]邱宗荫,尹一兵等.临床蛋白质组学[M].北京：科学出版社.2008,165-169.
[80]张雪群,姜颖,厉有名,等.人血浆低丰度蛋白伏击方法的研究进展.中华医学检验杂志[J].2006,29(10)：947-950.
[81]Wang K, Johnson A, Obradovic M, et al. TSE clearance during plasma products separation process by Gradiflow(TM) [J].Biologicals,2005,33:87-94.
[82]Cho S Y, Lee E, Lee J S, et al. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics,2005,5: 3386-3396.
[83]Wildgruber R, Harder A, Obermaier C, et al. Towards higher resolution: Two-dimentional electrophresis of saccharomyces cerevisiae proteins using overlapping narrow immobilized PH gradients [J]. Electrophoresis,2000,21:2610-2616.
[84]Fountoulakis M, Juranville JF, JiangL, et al. Depletion of the abundance plasma proteins. Amino Acids[J],2004,27:249-259.
[85]Moritz RL, Clipp ingdale AB, Kapp EA, et al. Application of 2-D free-flow electrophoresis/RP-HPLC for proteomic analysis of human plasma depleted of multihigh-abundance proteins [J]. Proteomics,2005,5:3402-3413.
[86]Tang H, Ali-Khan N, Echan LA, et al. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes [J]. Proteomics,2005,5:3329-3342.
[87]Bocchinfuso WP, lindzey JK, Hewitt SC. Induction of mammary gland development in estrogen receptor-alpha knockout mice [J]. Endocrinology,2000,141:2982-2994.
[88]Thomas E. Rohan, Abdissa Negassa, Rowan T.et al. Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease [J]. Cancer Epidemiology, Biomarkers & Prevention,2008,17:2337-2343.
[89]Carolyn J. Crandall, Arun Karlamangla, et al. Association of New-Onset Breast Discomfort with an Increase in Mammographic Density During Hormone Therapy [J]. Arch Intern Med,2006,166:1578-1584.
[90]Conner P. Breast response to menopausal hormone therapy-aspects on proliferation [J], apoptosis and mammographic density [J]. Ann,2007,39:28-41.
[91]饶金才,李兰珍,陈云生,等.乳腺增生病动物模型的复制及病理类型[J].中国病理生理杂志,1992,8(6)：671-672.
[92]林成仁,王敏,石体仁,等.乳腺增生病动物模型的建立及机理研究[J].中国中西医结合杂志,1997,17：270-272.
[93]余望贻,姜海斌,孟琼,等.乳腺增生病动物模型的实验研究[J].中国实验动物学报,2004,12(4)：25-238
[94]田国富.乳腺癌现代非手术治疗[M].科学技术文献出版社,2008,9.
[95]马南花,黎宗强,覃坚,等.雌性食蟹猴生理月经周期中雌激素变化与血脂水平关系的研究[J].广西医科大学学报,2008,25(3)：390-391
[96]冯力,张远慧,吴赛珠,等.不同剂量雌激素对去势雌兔血脂代谢的影响[J]第一军医大学学报,1998,121-122.
[97]Xia Zhang, Jei-Jun Jiao, Bhagu R. Regulation of human apolipoprotein A-1 gene expression by equine estrogens [J]. J Lipid Res,2001,42:1789-1801.
[98]Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer [J]. Cancer Treat Rev,2009, 35(2):175-184.
[99]Masteikova R, Muselik J, Bernatoniene J, et al. Antioxidant activity of tinctures prepared from hawthorn fruits and motherwort herb [J]. Ceska a Slovenska Farmacie, 2008,57:35-38.
[100]Lee MJ, Lee HS, Park SD, et al. Leonurus sibiricus herb extract suppresses oxidative stress and ameliorates hypercholesterolemia in C57BL/6 mice and TNF-alpha induced expression of adhesion molecules and lectin-like oxidized LDL receptor-1 in human umbilical vein endothelial cells [J]. Biosci, Biotech, Biochem,2010,74,279-284.
[101]陈承祺.乳腺增生病与内分泌激素的变化[J].标记免疫分析与临床,1999,6(2)：130-132.
[102]Fink G. Gonadotropin secretion and its control [J]. The Physiology of Reproduction, 1988,1349-1377.
[103]Ben-Jonathan N. Regulation of prolactin secretion. Ed. H Imura. New York:Raven Press.The Pituitary Gland,1994,261-283.
[104]林惠,郑登滋,胡励军.乳腺小叶增生与性腺轴平衡紊乱[J].中国医药学报,2000,78-79.
[105]J E Sanchez-Criado, J Martin de las Mulas, C Bellido. Gonadotrope oestrogen receptor-and-β and progesterone receptor immunoreactivity after ovariectomy and exposure to oestradiol benzoate, tamoxifen or raloxifene in the rat:correlation with LH secretion [J]. J Endocrinol,2005 184:59-68.
[106]Jose C Garrido-Gracia, Ana Gordon, Carmina Bellido.The integrated action of oestrogen receptor isoforms and sites with progesterone receptor in the gonadotrope modulates LH secretion:evidence from tamoxifen-treated ovariectomized rats [J]. J. Endocrinol,2007,193:107-119.
[107]Gill-Sharma M K, Gopalkrishnan K, Balasinor N, et al. Effects of tamoxifen on the fertility of male rats. Journal of Reproduction and Fertility,1993,99:395-402.
[108]Sijie Li, Bing Han, Guojin Liu. Immunocytochemical Localization of Sex Steroid Hormone Receptors in Normal Human Mammary Gland [J]. J Histochem and Cytochem,2010,58 (6):509-515.
[109]Lawson JS, Field AS, Tran DD. Breast cancer Incidence and estrogen receptor alpha in normal mammary tissue -an epidemiologic study among JapaneseWomen in Japan and Hawaii[J]. Int J Cancer,2002,97(5):685-687.
[110]Shyamala G, Chou YC, Louie SG. Cellular expression of estrogen and Progesterone receptors in mammary glands:regulation by hormones, development and aging [J]. Steroid Biochem Mol Biol,2002,80(2):137-148.
[111]Jennifer R. Wood, Varsha S. Likhite, Margaret A. Loven, et al. Allosteric Modulation of Estrogen Receptor Conformation by Dfferent Estrogen Response Elements[J]. Mol. Endocrinol,2001,15:1114-1120
[112]Savouret JF, Bailly A, Misrahi M, auch C, Redeuilh G,Chauchereau A. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene [J]. EMBO J,1991,10:1875-1883
[113]Hyun-Jung Kim, Xiaojiang Cui, Susan G. Hilsenbeck. Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer [J]. Clin. Cancer Res,2006,12:1013-1018.
[114]Schiff R, Massarweh SA, Shou J. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res,2004,10:331S-336S.
[115]Bardou VJ, Arpino G. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J]. J Clin Onco,2003,21(10):1973-1979.
[116]S. Park, H. Park, S. Choi. Expression of Androgen Receptor in Breast Cancer [J]. Cancer Res,2009,69:4156-4161.
[117]De Abreu F B, Pirolo L J, Canevari Rde A, et al. Shorter CAG Repeat in the AR Gene is Associated with Atypical Hyperplasia and Breast Carcinoma [J]. Anticancer Res, 2007,27:1199-1205
[118]Grant Buchanan, Stephen N. Birrell, Amelia A. Peters. Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate [J]. Cancer Res,2005,65:8487-8496.
[119]钱小红,贺福初等译,蛋白质组学从序列到功能,2002：39.
[120]M. Fountoulakis J.-F.Juranville,L.Jiang.Depletion of the high-abundance plasma proteins[J]. Amino Acids,2004,27:249-259
[121]Chertov O, Biragyn A, Kwak L W. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry[J].Proteomics,2004,4,1195-1203
[122]Craig A,Sidaway J,Holmes E,et al. Systems toxicology:integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat [J].J Proteome Res 2006,5,1586-1601
[123]Yan JX, Wait R, Berkelman T, Harry RA. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry [J].Electrophoresis,2000,21, 3666-3672.
[124]Tang WQ, Deng ZP, Oses-Prieto A,et al.Proteomics Studies of Brassinosteroid Signal Transduction Using Prefractionation and Two-dimensional DIGE [J].Mol.Cell. Proteomics,2008,7:728-738
[125]Lowery JT, Byers T, Kittelson J, et al.Differential expression of prognostic biomarkers between interval and screen-detected breast cancers:does age or family history matter? [J].Breast Cancer Res Treat.2011 Mar 24.
[126]Petricoin E F,Liot ta L A. Proteomic analysis at the bedside:early detection of cancer [J]. Trends Biotechnol,2002,20 (12 Sup2pl):S30-S34.
[127]Sauter ER, Zhu W, Fan XJ, et al. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer [J]. Br J Cancer,2002,86 (9):1440-1443.
[128]Luftner D, Possinger K. Nuclear mat rix proteins as biomarkers for breast cancer[J]. Expert Rev Mol Diagn,2002,2(1):23-31.
[129]Hamler RL, Zhu K, Buchanan NS, et al.A two-dimensional liquidphase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification[J]. Proteomics,2004,4(3):562-577.
[130]Chen ST, Pan TL, Tsai YC, et al. Proteomics reveals protein profile changes in doxorubicin-treated MCF27 human breast cancer cells[J]. Cancer Lett,2002, 181(1)95-107.
[131]Rui Z, Jian Guo J, Yuan-Peng T, et al. Use of serological proteomic met hods to find biomarkers associated wit h breast cancer [J]. Proteomics,2003,3 (4):433-439.
[132]Ahn SH, Sawada H, Ro JY, et al. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp. Metastasis[J].1997,15:151-156.
[133]Mulla A, Christian HC, Solito E et al. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma[J]. Clin Endocrinol (Oxf),2004,60:107-119.
[134]Shen D, Nooraie F, Elshimali Y,et al. Decreased expression of annexin Al is correlated with breast cancer development and progression as determined by a tissue microarray analysis [J]. Hum. Pathol,2006,37:1583-1591.
[135]Alldridge LC, Harris HJ, Plevin R, et al. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway [J]. J. Biol. Che,1999,274,37620-37628.
[136]Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1[J]. J. Steroid Biochem. Mol. Biol.2000,74:311-317.
[137]Estrogen-1 nduced reactive oxygen species-mediated signalings contribute to breast cancer [J].Biochim Biophys Acta.2011 Jan; 1815(1):115-133.
[138]Mobley JA, Brueggemeier RW, et al. Brueggemeier estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer [J]. Carcinogenesis 2004,25,3-9.
[139]Sastre-Serra J. Valle A, Company MM, et al.Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer [J]. Free Radic. Biol. Med. 2010,48,506-512.
[140]Marta W, Urszula KK. Cytoprotective action of 17β-oestradiol against iron-Ⅰ nduced hepatic oxidative stress in vitro [J]. Bull Vet. Inst. Pulawy,2010,54:259-263.
[141]Mense SM, Remotti F, Bhan A, et al. Estrogen-Ⅰ nduced breast cancer:alterations in breast morphology and oxidative stress as a function of estrogen exposure [J]. Toxicol Appl. Pharmacol.2008,232:78-85.
[142]Parmar H, Melov S, Samper E, et al. Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase [J]. Breast 2005,14:256-263.
[143]Kim SU, Hwang CN, Sun HN, et al. Peroxiredoxin I is an indicator of microglia activation and protects againsthydrogen peroxide-mediatedmicroglial death [J]. Biol. Pharm. Bull.2008,31:820-825.
[144]Immenschuh S.; Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation [J]. Antioxid Redox Signal.2005,7:768-777.
[145]Lee YM, Park SH, Shin DI et al. Oxidative modification of peroxiredoxin is associated with drug-Ⅰ nduced apoptotic signaling in experimental models of Parkinson disease[J]. J. Biol. Chem.2008,283:9986-9998.
[146]Noh D Y, Ahn S J, Lee R A, Overexpression of peroxiredoxin in human breast caneer[J]. Antcancer Res,2001,21(3B):2085-2090.
[147]Karihtala P,Mantyniemi A,Kang S W,et al. Peroxiredoxins in breast carcinoma [J].Clin Cancer Res,2003,9(9):3418-3424.
[148]Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases [J]. Annu. Rev. Pharmacol Toxicol.2005,45:51-88.
[149]Meiers I, Shanks JH. Bostwick DG.Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer:review 2007[J]. Pathology 2007,39:299-304.
[150]Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis [J]. Virchows. Arch.2007,450:637-642.
[151]McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy [J]. Oncogene 2006,25:1639-1648.
[152]Parcellier A, Schmitt E, Brunet M,et al. Small heat shock proteins HSP27 and a B-crystallin:cytoprotective and oncogenic functions [J]. Antioxid Redox Signal.2005, 7:404-413.
[153]周英,文海泉.热休克蛋白27在皮肤基底细胞癌和鳞状细胞癌中的表达[J].中华皮肤科杂志.2001,34(5)：381.
[154]O'Neill AP, Shaaban MA, West RC, et al. Inereasedriskofmalignant Progression in benign Proliferating breast lesions defined by expression of heatshoek Protein 27[J]. Br J Caneer.2004.90(1):182-188.
[155]Ahmad MF, Raman B, Ramakrishna T, Rao Ch M. Effect of phosphorylation on alpha B - crystallin:differences in stability, subunit exchange and chaperone activity of homo and mixed oligomers of alpha B - crystallin and its phosphorylation -mimicking mutant [J]. J.Mol. Biol.2008,375,1040-1051.
[156]Kamradt, M.C.; Chen, F.; Sam, S.; Cryns, V.L.The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J. Biol. Chem.2002,277,38731-38736.
[157]Sitterding SM, Wiseman W R, Schiller C L, et al. AlphaB-crystallin:a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann. Diagn. Pathol.2008,12(1), 33-40.